Large B-cell lymphoma (LBCL) is the most common aggressive non-Hodgkin lymphoma, with about 60% of patients cured by first-line therapy. Relapsed or refractory (R/R) patients have poor outcomes, with median survival around 6.3 months. Autologous CD19 CAR T-cell therapies help some patients but are limited by manufacturing delays, disease aggressiveness, and access barriers.
Cemacabtagene ansegedleucel (cema-cel) and ALLO-501 are off-the-shelf allogeneic CD19 CAR T-cell therapies derived from healthy donors. Gene editing reduces graft-versus-host disease risk and allows rapid treatment without patient T-cell collection. Phase I studies in 33 R/R LBCL patients showed median enrollment-to-treatment time of 2 days. Safety was favorable, with no severe cytokine release syndrome, neurotoxicity, or graft-versus-host disease. Common adverse events included neutropenia, anemia, and thrombocytopenia.
Efficacy was promising: overall response reached 67% with 58% complete response for the phase II regimen. CAR T-cell expansion correlated with response, independent of HLA matching. These findings suggest allogeneic CAR T therapy is a safe, effective, and immediately available option for R/R LBCL, potentially changing treatment paradigms.